Pharmaron Beijing Co., Ltd. Class H (HK:3759)
:3759
Want to see HK:3759 full AI Analyst Report?
3759 Stock Chart & Stats
HK$24.14
HK$0.24(1.88%)
At close: 4:00 PM EST
HK$24.14
HK$0.24(1.88%)
Day’s Range― - ―
52-Week RangeHK$14.98 - HK$30.12
Previous CloseN/A
Volume1.90M
Average Volume (3M)3.76M
Market Cap
HK$45.39B
Enterprise ValueHK$41.80B
Total Cash (Recent Filing)HK$2.97B
Total Debt (Recent Filing)HK$7.08B
Price to Earnings (P/E)24.5
Beta1.99
Next Earnings
Aug 31, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio-2.69
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.03Price Target Upside20.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$18.64B
Bulls Say, Bears Say
Bulls Say
Integrated Discovery-to-manufacturing ModelOwning capabilities across discovery, preclinical/clinical development and manufacturing creates client stickiness and cross-sell potential. This end-to-end model diversifies revenue sources, increases customer lifetime value, and supports durable contract flow across the drug lifecycle.
Low Leverage, Stronger Balance SheetA low TTM debt-to-equity (~0.23) and growing shareholders' equity give the company financial flexibility to fund capacity investments and absorb cycles. This reduces refinancing risk and supports bidding on long-term CDMO contracts over the medium term.
Solid Operating ProfitabilityMid-teens EBIT and near-12% net margins provide an earnings cushion to support reinvestment in labs and capacity. Sustainable margins help preserve operating cash flow, maintain service quality, and support returns even if revenue growth moderates.
Bears Say
Weak, Volatile Cash ConversionOperating cash covers only ~39% of net income and FCF is small and recently fell sharply. Volatile cash conversion limits the firm's ability to self-fund capex or working-capital needs, raising reliance on external financing and increasing execution risk.
Slowing Revenue GrowthTTM revenue growth slowed to ~3.2% from prior faster expansion. Persistent top-line deceleration can signal market saturation, intensified competition, or pricing pressure, making medium-term earnings gains dependent on winning larger, higher-margin programs.
Margin Compression Since 2021Meaningful margin compression versus 2021 points to structural pressures—cost inflation, pricing weakness, or adverse mix. Continued margin erosion would reduce free cash flow and the return on new contracts, constraining reinvestment and long-term profitability.
Pharmaron Beijing Co., Ltd. Class H News
3759 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$14.98 and its highest was HK$30.12 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$45.39B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 87 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.212 earnings per share for the quarter, missing the consensus estimate of HK$0.24 by -HK$0.028.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays a Annually dividend of HK$0.219 which represents an annual dividend yield of 1.04%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.29.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.212 in its last earnings report, missing expectations of HK$0.24. Following the earnings report the stock price went up 5.922%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
11.22%
Trailing 12-Months
Asset Growth
15.52%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. Class H (3759) is a leading contract research organization (CRO) offering a comprehensive range of R&D and manufacturing services to the pharmaceutical and biotechnology sectors. Founded in Beijing, China, Pharmaron provides integrated services in discovery, development, and manufacturing, covering various stages of drug research and production. The company's core services include drug discovery, preclinical research, clinical development, and commercial manufacturing, serving clients across the globe.
3759 Stock 12 Month Forecast
Average Price Target
HK$29.03
▲(20.25% Upside)
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---